Measures of Treatment Workload for Patients With Breast Cancer
Authors:
- 1 December 2019
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 3 (3) , 1-10
Abstract
PURPOSE: Patients with breast cancer spend a large amount of time and effort receiving treatment. When the number of health care tasks exceeds a patient’s ability to manage that workload, they could become overburdened, leading to decreased plan adherence. We used electronic health record data to retrospectively assess dimensions of treatment workload related to outpatient encounters, commuting, and admissions. METHODS: Using tumor registry and scheduling data, we evaluated the sensitivity of treatment workload measures to detect expected differences in breast cancer treatment burden by stage. We evaluated the impact of the on-body pegfilgrastim injector on the treatment workload of patients undergoing a specific chemotherapy protocol. RESULTS: As hypothesized, patients with higher stage cancer experienced higher treatment workload. Over the first 18 months after diagnosis, patients with stage III disease spent a median of 81 hours (interquartile range [IQR], 39 to 113 hours) in outpatient clinics, commuted 61 hours (IQR, 32 to 86 hours), and spent $1,432 (IQR, $690 to $2,552) in commuting costs. In contrast, patients with stage I disease spent a median of 29 hours (IQR, 18 to 46 hours in clinic), commuted for 34 hours (IQR, 19 to 55 hours), and spent $834 (IQR, $389 to $1,649) in commuting costs. In addition, we substantiated claims that the pegfilgrastim on-body injector was effective in reducing some dimensions of workload such as unique appointment days. CONCLUSION: Treatment workload measures capture an important dimension in the experience of patients with cancer. Patients and health care organizations can use workload measures to plan and allocate resources, leading to higher quality and better coordinated care.Keywords
This publication has 28 references indexed in Scilit:
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's ExperienceThe Oncologist, 2013
- Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practiceJournal of Clinical Epidemiology, 2012
- Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditionsBMC Medicine, 2012
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II StudiesJournal of Oncology Practice, 2010
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical TrialsJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.Supportive Care in Cancer, 2008
- Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregiversCanadian Medical Association Journal, 2004
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Helping Patients Follow Prescribed TreatmentJAMA, 2002